EXEL · Exelixis, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $610.81M | $597.75M | $568.26M | $555.45M | $539.54M | $637.18M | $425.23M | - | $471.92M | $469.85M |
| Cost of Revenue | $19.95M | $18.57M | $19.47M | $19.17M | $17.33M | $17.67M | $21.26M | - | $18.77M | $17.70M |
| Gross Profit | $590.86M | $579.18M | $548.79M | $536.27M | $522.21M | $619.51M | $403.97M | - | $453.15M | $452.14M |
| R&D | $199.92M | $199.16M | $200.36M | $212.23M | $222.57M | $211.15M | $227.69M | - | $332.58M | $232.57M |
| SG&A | $139.60M | $123.66M | $134.86M | $137.18M | $111.80M | $132.01M | $113.98M | - | $138.14M | $141.72M |
| Total Operating Expenses | $359.47M | $361.21M | $354.69M | $368.59M | $403.47M | $361.30M | $395.76M | - | $489.50M | $392.00M |
| D&A | $6.95M | - | - | $7.34M | - | - | $6.38M | - | - | - |
| Operating Income | $251.34M | $236.54M | $213.58M | $186.86M | $136.07M | $275.87M | $29.46M | - | ($17.58M) | $77.85M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $57.22M | $58.84M | $45.57M | $46.07M | $36.78M | $66.73M | $11.95M | - | $4.78M | $19.21M |
| Net Income | $210.47M | $193.58M | $184.85M | $159.62M | $117.97M | $226.12M | $37.32M | - | $1.04M | $81.18M |
| EPS - Basic | $0.81 | $0.72 | $0.68 | $0.57 | $0.41 | $0.78 | $0.12 | - | $0.00 | $0.25 |
| EPS - Diluted | $0.79 | $0.69 | $0.65 | $0.55 | $0.40 | $0.77 | $0.12 | - | $0.00 | $0.25 |
Balance Sheet
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $226.15M | $376.30M | $164.43M | $183.75M | $258.35M | $198.46M | $259.56M | $262.99M | $396.86M | $464.48M |
| Accounts Receivable | $328.95M | $309.73M | $292.35M | $281.64M | $269.71M | $396.58M | $240.58M | $237.41M | $248.11M | $232.82M |
| Inventory | $26.61M | $27.40M | $23.48M | $24.85M | $21.01M | $20.61M | $21.11M | $17.32M | $24.98M | $28.64M |
| Accounts Payable | $24.15M | $25.35M | $25.82M | $42.84M | $59.31M | $28.68M | $26.07M | $33.77M | $26.45M | $25.99M |
| Current Assets | $1.21B | $1.40B | $1.18B | $1.40B | $1.55B | $1.48B | $1.29B | $1.32B | $1.44B | $1.59B |
| Total Assets | $2.59B | $2.82B | $2.68B | $2.84B | $2.96B | $2.77B | $2.80B | $2.94B | $2.98B | $3.14B |
| Current Liabilities | $370.98M | $373.78M | $336.11M | $399.10M | $394.35M | $345.70M | $373.01M | $394.28M | $376.82M | $339.62M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $657.85M | $662.85M | $644.54M | $706.22M | $684.86M | $653.39M | $675.74M | $678.45M | $629.29M | $614.53M |
| Stockholders' Equity | $1.94B | $2.16B | $2.03B | $2.13B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B |
| Retained Earnings | ($215.79M) | ($106.06M) | ($219.54M) | ($163.29M) | ($90.29M) | ($199.97M) | ($258.95M) | ($173.35M) | ($126.05M) | $11.19M |
Cash Flow
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $251.84M | - | - | $211.44M | - | - | $68.82M | - | - | - |
| Investing Cash Flow | ($51.07M) | - | - | $49.76M | - | - | $111.79M | - | - | - |
| Financing Cash Flow | ($457.11M) | - | - | ($294.82M) | - | - | ($184.05M) | - | - | - |
| CapEx | $1.51M | - | - | $2.95M | - | - | $9.69M | - | - | - |
| Free Cash Flow | $250.34M | - | - | $208.49M | - | - | $59.13M | - | - | - |
Ratios
| Metric | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 96.7% | 96.9% | 96.6% | 96.5% | 96.8% | 97.2% | 95.0% | - | 96.0% | 96.2% |
| Operating margin | 41.1% | 39.6% | 37.6% | 33.6% | 25.2% | 43.3% | 6.9% | - | -3.7% | 16.6% |
| EBITDA margin | 42.3% | - | - | 35.0% | - | - | 8.4% | - | - | - |
| Net margin | 34.5% | 32.4% | 32.5% | 28.7% | 21.9% | 35.5% | 8.8% | - | 0.2% | 17.3% |
| Free cash flow margin | 41.0% | - | - | 37.5% | - | - | 13.9% | - | - | - |
| FCF / Net income | 1.19 | - | - | 1.31 | - | - | 1.58 | - | - | - |
| R&D / Revenue | 32.7% | 33.3% | 35.3% | 38.2% | 41.3% | 33.1% | 53.5% | - | 70.5% | 49.5% |
| SG&A / Revenue | 22.9% | 20.7% | 23.7% | 24.7% | 20.7% | 20.7% | 26.8% | - | 29.3% | 30.2% |
| Effective tax rate | 21.4% | 23.3% | 19.8% | 22.4% | 23.8% | 22.8% | 24.3% | - | 82.1% | 19.1% |
| Return on assets | 8.1% | 6.9% | 6.9% | 5.6% | 4.0% | 8.2% | 1.3% | - | 0.0% | 2.6% |
| Return on equity | 10.9% | 9.0% | 9.1% | 7.5% | 5.2% | 10.7% | 1.8% | - | 0.0% | 3.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.26 | 3.75 | 3.51 | 3.50 | 3.93 | 4.27 | 3.46 | 3.34 | 3.83 | 4.68 |
| Quick ratio | 3.19 | 3.68 | 3.44 | 3.44 | 3.88 | 4.21 | 3.41 | 3.30 | 3.76 | 4.60 |
| Cash ratio | 0.61 | 1.01 | 0.49 | 0.46 | 0.66 | 0.57 | 0.70 | 0.67 | 1.05 | 1.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.34 | 1.31 | 1.32 | 1.33 | 1.30 | 1.31 | 1.32 | 1.30 | 1.27 | 1.24 |
| Liabilities / Assets | 0.25 | 0.23 | 0.24 | 0.25 | 0.23 | 0.24 | 0.24 | 0.23 | 0.21 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | 0.24 | 0.21 | 0.21 | 0.20 | 0.18 | 0.23 | 0.15 | - | 0.16 | 0.15 |
| Inventory turnover | 0.75 | 0.68 | 0.83 | 0.77 | 0.82 | 0.86 | 1.01 | - | 0.75 | 0.62 |
| Days sales outstanding | 197d | 189d | 188d | 185d | 182d | 227d | 207d | - | 192d | 181d |
| Days inventory outstanding | 487d | 538d | 440d | 473d | 443d | 426d | 362d | - | 486d | 590d |
| Days payable outstanding | 442d | 498d | 484d | 816d | 1249d | 592d | 448d | - | 514d | 536d |
| Cash conversion cycle | 241d | 229d | 144d | -157d | -624d | 61d | 121d | - | 163d | 235d |
| Valuation | ||||||||||
| P / E | 55.5x | 58.1x | 71.0x | 62.9x | 64.9x | 29.2x | 197.8x | - | - | 76.4x |
| P / B | 6.1x | 5.2x | 6.5x | 4.7x | 3.3x | 3.1x | 3.4x | - | 3.0x | 2.5x |
| P / S | 19.2x | 18.7x | 23.1x | 17.9x | 14.0x | 10.4x | 17.1x | - | 14.8x | 13.3x |
| EV / EBITDA | 44.5x | - | - | 50.4x | - | - | 195.1x | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 10.0% | 10.8% | -10.8% | 30.6% | 14.3% | 35.6% | 4.0% | - | 14.6% | 12.0% |
| Revenue CAGR (3y) | 14.3% | 13.2% | 10.7% | 16.0% | 18.0% | 18.3% | 16.3% | - | 20.2% | 21.9% |
| Revenue CAGR (5y) | 17.7% | 17.1% | 17.0% | 19.6% | 14.7% | 21.5% | 14.6% | - | 15.9% | 20.3% |
| Gross profit growth (YoY) | 10.2% | 10.9% | -11.4% | 32.8% | 15.2% | 37.0% | 2.4% | - | 14.3% | 11.4% |
| Operating income growth (YoY) | 34.5% | 73.8% | -22.6% | 534.2% | - | 254.4% | 2.2% | - | - | -7.0% |
| Net income growth (YoY) | 31.9% | 64.1% | -18.3% | 327.7% | 11232.7% | 178.5% | -6.8% | - | -98.6% | 14.9% |
| EPS growth (YoY) | 43.6% | 72.5% | -15.6% | 358.3% | - | 208.0% | 0.0% | - | - | 13.6% |
| EPS CAGR (3y) | 87.4% | 44.2% | 43.5% | 37.8% | 49.4% | 36.9% | - | - | - | 6.0% |
| EPS CAGR (5y) | - | - | 25.4% | 29.7% | 5.2% | 25.2% | -12.9% | - | - | -2.2% |
| FCF growth (YoY) | 20.1% | - | - | 252.6% | - | - | -18.3% | - | - | - |
| FCF CAGR (5y) | 57.3% | - | - | 31.5% | - | - | -18.0% | - | - | - |
| Book value growth (YoY) | -9.2% | -5.0% | -4.1% | 0.1% | -3.1% | -16.1% | -16.7% | -9.0% | -5.8% | 5.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-01-02.
Business segments
$2.32B totalReportable Segment$2.32B · 100.0%
Product / service
$6.76B totalProduct Gross$3.01B · 44.5%
Product$2.12B · 31.4%
Cabometyx$2.11B · 31.2%
License$214.38M · 3.2%
Collaboration$197.32M · 2.9%
Cometriq$9.44M · 0.1%
Service($17.05M) · -0.3%
Product Sales Discounts And Allowances($889.00M) · -13.1%
Geographic
$2.32B totalUS$2.14B · 92.3%
Europe$154.16M · 6.6%
JP$25.59M · 1.1%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing EXELIXIS against the 5 most active filers in the same SIC group.